Advertisement
Advertisement
REPL
Replimune Group, Inc.
12.06
USDSponsored
-0.80
-6.22%
Aug 07, 15:59 UTC -4
Closed
After-Market
11.97
-0.09
-0.73%
REPL Earnings Reports
Positive Surprise Ratio
REPL beat 16 of 32 last estimates.
50%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q2 27 (Revenue/ EPS)
$1.35M
/-$0.56
Implied change from Q1 27 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/-37.78%
Replimune Group, Inc. earnings per share and revenue
On Aug 05, 2026, REPL reported earnings of -- USD per share (EPS) for Q1 27, -- the estimate of -0.69 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 204.00 thousand, with a --% difference.
Looking ahead to Q2 27, 4 analysts forecast an EPS of -0.56 USD, with revenue projected to reach 1.35 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Replimune Group, Inc.'s earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Replimune Group, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Replimune Group, Inc.'s Q1 2027 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Replimune Group, Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Replimune Group, Inc.'s next earnings report?
Based on 4
analysts, Replimune Group, Inc. is expected to report EPS of -$0.56 and revenue of $1.35M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement